GlobeNewswire by notified

Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD

Share

`

Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD

Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET, Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, today announces important progress in its preclinical program targeting Geographic Atrophy (GA), a severe and underserved form of Age-Related Macular Degeneration (AMD).

This recently launched program has reached the first step with the identification of 50 targets that have the potential to provide better treatment options for GA. These targets are derived from a cutting-edge CRISPR-based target discovery platform, which consists in a genome-wide screening in a phenotypic cellular assay reflective of GA disease.

The preclinical team successfully already confirmed the potential of several of these targets across various relevant in vitro models. Next step is to continue the in vitro validation of the remaining identified targets and start their evaluation in GA animal models.

Looking ahead, Oxurion anticipates finalizing the selection of the top three targets in the fourth quarter of this year and to initiate the lead generation process, aiming to file intellectual property (IP) early 2025.

Pascal Ghoson, CEO of Oxurion, shares his enthusiasm: "By moving beyond traditional approaches focused on the complement pathway alone, our platform has opened new avenues for understanding and treating AMD/GA. The progress we have made paves the way for new therapies in a market estimated to be worth $3-6 billion by 2028. These advances strengthen our position to transform the treatment of retinal degenerative diseases."

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is headquartered in Leuven, Belgium. More information is available at www.oxurion.com

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

.

Contacts :

OXURION NV

Pascal Ghoson, CEO
pascal.ghoson@oxurion.com

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Weekly share repurchase program transaction details29.5.2024 18:33:44 CEST | Press release

May 29, 2024 SBM Offshore reports the transaction details related to its EUR65 million (c. US$70 million) share repurchase program for the period May 23, 2024 through May 29, 2024. The repurchases were made under the EUR65 million share repurchase program announced on February 29, 2024 and effective from March 1, 2024. The objective of the program is to reduce share capital. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period March 1, 2024 through May 29, 2024 can be found in the top half of the table below. Further detailed information regarding both the progress of the share repurchase program and all individual transactions can be accessed via the Investors section of the Company’s website. Share Repurchase ProgramOverall progress Share Repurchase Program:Total Repurchase AmountEUR 65,000,000Cumulative Repurchase AmountEUR 21,944,332Cumulative Quantity Repurchased1,553,031Cumulative Ave

Progress on cosmetics plant project: completion of the basic engineering phase and success of the related test campaign29.5.2024 17:45:00 CEST | Press release

PRESS RELEASE Progress on cosmetics plant project: completion of the basic engineering phase and success of the related test campaign Evry, 29 May 2024 – 05:45 p.m.: Global Bioenergies has successfully completed the basic engineering phase of its plant project dedicated to the cosmetics markets whose commissioning is scheduled for mid-2027. The engineering work carried out as part of the basic engineering has precisely defined the each of the units that will enable the fully integrated production of cosmetic-grade isobutene derivatives. It also confirms the project schedule and the nominal CAPEX of 65 million euros (i.e. a maximum CAPEX of 80 million euros taking into account contingencies). Roland Desvignes, Industrial Director of Global Bioenergies, explains: “Two engineering firms have been mandated, the first to handle the biological side, and the second the part dedicated to green chemistry. Their respective expertise gives us a very good vision of the plant's blueprints. We are n

Vaisala Corporation: Share Repurchase 29.5.202429.5.2024 17:30:00 CEST | Press release

VAISALA CORPORATIONSTOCK EXCHANGE RELEASE 29.5.2024Vaisala Corporation: Share Repurchase 29.5.2024In the Helsinki Stock ExchangeTrade date 29.5.2024Bourse trade BuyShare VAIASAmount 500SharesAverage price/ share 39,9700EURTotal cost 19 985,00EURVaisala Corporation now holds a total of 138 828 sharesincluding the shares repurchased on 29.5.2024On behalf of Vaisala CorporationNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information Paula Liimattatel +358 9 8949 2020, ir@vaisala.comwww.vaisala.com Vaisala is a global leader in measurement instruments and intelligence for climate action. We equip our customers with devices and data to improve resource efficiency, drive energy transition, and care for the safety and well-being of people and societies worldwide. With almost 90 years of innovation and expertise, we employ a team of over 2,300 experts committed to taking every measure for the planet. Vaisala series A shares are listed on the Nasdaq Helsinki stock exchange.vaisala.com

Thierry Amarger co-opted as independent Director by Vantiva29.5.2024 17:30:00 CEST | Press release

Press Release Thierry Amarger co-opted as independent Director by Vantiva Paris, France – May 29, 2024 – Vantiva (Euronext Paris: VANTI), announced that on the recommendation of the Governance and Social Responsibility Committee, Vantiva's Board of Directors, convened on May 28, 2024, to co-opt Thierry Amarger as an independent Director of Vantiva. He replaces Dominique D'Hinnin, who resigned on April 5, 2024. This co-option took effect immediately. Thierry Amarger's co-option will be submitted to shareholders for ratification at the Annual General Meeting to be held on June 19, 2024. His term of office will expire at the close of the Annual General Meeting for fiscal year 2024. Brian Shearer, Chairman of the Board of Directors, said: “I welcome Thierry Amarger to our Board of Directors. He is a proven leader within multiple areas of the global telecommunications ecosystem, and his skillset will be immediately beneficial to all Vantiva stakeholders.” Mr. Amarger, a French national, is

Zealand Pharma to participate in upcoming healthcare investor conferences in June 202429.5.2024 17:10:00 CEST | Press release

Press release – No. 5 / 2024 Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024 Copenhagen, Denmark, May 29, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that Adam Steensberg, President and CEO, will participate in fireside chats at the following healthcare investor conferences in June: Jefferies Global Healthcare Conference, June 4-6 in New York City Wednesday, June 5 at 10:00 a.m. ET (4:00 p.m. CET) A webcast of the fireside chat will be available at https://wsw.com/webcast/jeff302/register.aspx?conf=jeff302&page=zeal&url=https://wsw.com/webcast/jeff302/zeal/1839808 and accessible through the Events page in the Investor section of Zealand Pharma’s website at https://www.zealandpharma.com/events/ where a replay will also be archived after the fireside chat. Goldman Sachs 45th Annual Global Healthcare Conference, Jun

HiddenA line styled icon from Orion Icon Library.Eye